Read "Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups" at NAP.edu The Dihexa story Most hyped brain peptide of the decade. "10,000,000x more potent than BDNF." Based on one paper retracted in 2021. Swipe through all 7 slides. For research purposes only. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high risk HER2 positive early breast cancer (DESTINY Breast11): a randomised, open label, multicentre, phase III trial Annals of Oncology Participant Diversity by Race, Ethnicity, and Sex in Rare Disease Clinical Trials: A Case Study of Eight Rare Cancers NCBI Bookshelf